A new approach to gene therapy for cystic fibrosis is offering hope for patients who don’t respond to existing treatments. Researchers at UCLA have developed a method using lipid nanoparticles – the same technology behind some mRNA vaccines – to deliver a healthy copy of the CFTR gene directly into lung cells. This breakthrough, published in UCLA Health News, could pave the way for a “one-time” treatment for the genetic disease, rather than the ongoing medication many patients currently require.
Cystic fibrosis affects over 70,000 people worldwide, according to the Cystic Fibrosis Foundation. It’s caused by mutations in the CFTR gene, which controls the flow of salt and water in and out of cells. This leads to a buildup of thick mucus in the lungs, digestive system, and other organs, causing severe respiratory problems and digestive issues. While newer drugs called CFTR modulators have significantly improved the lives of many with cystic fibrosis, they don’t function for everyone. Approximately 10% of patients have mutations that result in little to no functional CFTR protein, leaving them with limited treatment options.
The UCLA team’s innovation centers around the utilize of lipid nanoparticles to deliver the genetic material needed to correct the faulty gene. Unlike traditional gene therapies that often rely on viral vectors – which can trigger immune responses and have limitations in the amount of genetic material they can carry – lipid nanoparticles offer a non-viral alternative. These tiny, fat-based particles can be engineered to transport the CRISPR-Cas9 gene-editing machinery, guide molecules, and a complete, functional CFTR gene directly into airway cells.
Packaging the Complete Gene for Precise Editing
A key challenge in gene therapy has been delivering large genes like CFTR. “Getting all of that into a single particle – especially a gene as large as CFTR – is something that hadn’t been shown before,” explained Ruth Foley, the study’s first author and a recent PhD graduate from the Jonas lab at UCLA, as reported by UCLA Newsroom. The researchers successfully packaged all the necessary components into a single nanoparticle, allowing for precise gene insertion without the risks associated with viral vectors.
In laboratory tests using human airway cells with a severe cystic fibrosis mutation, the nanoparticles successfully delivered the healthy CFTR gene into 3-4% of the cells. Remarkably, this relatively small correction rate resulted in a restoration of 88% to 100% of normal CFTR channel function across the entire cell population. This high level of recovery is attributed to a gene design strategy, known as codon optimization, developed by collaborators in Dr. Donald Kohn’s lab at UCLA. This optimization maximizes protein production from the newly inserted gene, amplifying its effect even in a limited number of cells.
Beyond Symptom Management: A Potential Cure
Current treatments for cystic fibrosis primarily focus on managing symptoms, such as clearing mucus from the lungs and preventing infections. While these therapies improve quality of life, they don’t address the underlying genetic defect. Gene therapy, in contrast, aims to correct the root cause of the disease by providing cells with a functional copy of the CFTR gene. “For those patients, gene therapy isn’t just an improvement – it’s really the only option,” said Brigitte Gomperts, co-author of the study and associate director of translational research at the stem cell center.
The UCLA team’s approach differs from other gene therapies that deliver messenger RNA (mRNA), which requires repeated doses. By inserting the corrected gene directly into the genome, the hope is that cells and their descendants will continue to produce functional CFTR protein over the long term. However, researchers emphasize that reaching airway stem cells – the cells responsible for regenerating the airway lining – is crucial for a lasting effect. These stem cells are located deep within the lung tissue and are difficult to access.
A Versatile Platform for Future Therapies
The potential of this technology extends beyond cystic fibrosis. As lipid nanoparticles are adaptable and don’t rely on viral components, they could be used to deliver gene therapies for other genetic lung diseases and potentially even conditions affecting other tissues. “This kind of platform gives you room to iterate,” Foley explained. “If you require to re-dose or adapt the cargo for a different disease, you’re not starting from scratch.”
Steven Jonas, senior author of the study and a member of the UCLA Broad Stem Cell Research Center, cautioned that this research is still in its early stages. “This paper is a proof of concept,” he said. “It shows that we can package and deliver the right genetic cargo. The next challenge is getting it to the right cells in the body.” Further research will focus on improving delivery methods to target airway stem cells and ensuring the long-term safety and efficacy of this novel gene therapy approach.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The researchers are continuing to refine their delivery methods and plan to conduct further studies to assess the long-term effects of this gene therapy approach. The next step will involve testing the therapy in animal models before moving to human clinical trials, a process that could take several years. Readers interested in learning more about cystic fibrosis and ongoing research can visit the Cystic Fibrosis Foundation website.
What are your thoughts on this promising new approach to treating cystic fibrosis? Share your comments below, and please share this article with anyone who might find it helpful.
Keep reading
